DNER and cancer: Several BET inhibitors are currently being evaluated in phase I or phase II clinical trials for cancer treatment, including ZEN-3694, OTX015/MK-8628, AZD5153, and GSK525762/I-BET762.137, 138, 139, 140, 141 Due to the limited therapeutic activity of BET inhibitors, it is alternative to combine with other epigenetic reagents.142